Companies sponsors |
Taiho Pharma Europe (futibatinib) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
AMMF – The Cholangiocarcinoma Charity |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
Associated public health groups |
None |
Comparator companies |
Incyte Biosciences (pemigatinib) (confidentiality agreement returned, participating) |
|
Hospira UK (fluorouracil, oxaliplatin) (confidentiality agreement not returned, not participating) |
|
Medac (folinic acid, fluorouracil, oxaliplatin) (confidentiality agreement not returned, not participating) |
|
Ranbaxy, a Sun Pharmaceutical company (oxaliplatin) (confidentiality agreement not returned, not participating) |
|
Seacross Pharmaceuticals (oxaliplatin) (confidentiality agreement not returned, not participating) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |